51ÔÚÏß

Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
Return to PRWeb homepage
  • News
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • 51ÔÚÏß
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • ·¡²Ô±¹¾±°ù´Ç²Ô­³¾±ð²Ô³Ù

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All ·¡²Ô±¹¾±°ù´Ç²Ô­³¾±ð²Ô³Ù

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • °Õ±ð±ô±ð³¦´Ç³¾³¾Â­³Ü²Ô¾±³¦²¹³Ù¾±´Ç²Ô²õ

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All °Õ±ð±ô±ð³¦´Ç³¾³¾Â­³Ü²Ô¾±³¦²¹³Ù¾±´Ç²Ô²õ

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • 51ÔÚÏß PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • RSS
  • 51ÔÚÏß
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • ·¡²Ô±¹¾±°ù´Ç²Ô­³¾±ð²Ô³Ù
    • Heavy Industry & Manufacturing
    • °Õ±ð±ô±ð³¦´Ç³¾³¾Â­³Ü²Ô¾±³¦²¹³Ù¾±´Ç²Ô²õ
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • RSS
  • RSS
  • RSS

Viablife Achieves U.S. FDA No Objection for Highly-Scalable Biosynthesized Hydroxytyrosol in Collaboration with REJIMUS, INC.


News provided by

REJIMUS, INC.

Feb 24, 2025, 06:05 ET

Share this article

Share toX

Share this article

Share toX

REJIMUS
REJIMUS

HANGZHOU, China, Feb. 24, 2025 /PRNewswire-PRWeb/ -- Hangzhou Viablife Biotech Co., Ltd., a leading innovator in biosynthesis and biofermentation technologies for food and dietary supplement ingredients, proudly announces that its highly-scalable biosynthesized Hydroxytyrosol has received "No Objection" from the U.S. Food and Drug Administration (FDA) for its Generally Recognized as Safe (GRAS) Notification on a scientific basis.

Hangzhou Viablife Biotech Co., Ltd., a leading innovator in biosynthesis and biofermentation technologies for food and dietary supplement ingredients, proudly announces that its highly-scalable biosynthesized Hydroxytyrosol has received "No Objection" from the U.S. Food and Drug Administration (FDA) for its Generally Recognized as Safe (GRAS) Notification on a scientific basis.

Viablife's success in obtaining GRAS Status from the FDA reflects the company's dedication to high-quality, purpose-driven food ingredient innovation and services, which perfectly aligns with our mission...

Post this

This achievement was made possible through Viablife's collaboration with REJIMUS, INC., a top-tier FDA regulatory consultancy based in the United States, having a dedicated department specializing in GRAS and NDI Notifications with an unprecedented track record of successful first-time FDA Notifications. With REJIMUS' expertise in GRAS assessments, regulatory submissions, and the business strategies around getting ingredients to market, Viablife successfully navigated the rigorous scientific and safety evaluation process required by the FDA.

Hydroxytyrosol, a powerful polyphenol is naturally found in olives, and is well known for its potent antioxidant properties and significant health benefits, particularly in cardiovascular and neuroprotective support. Viablife's patented biosynthesis technology enables the sustainable and efficient production of high-purity Hydroxytyrosol at commercial scale, offering an environmentally friendly alternative to traditional extraction methods and competing ingredients in the marketplace. This milestone reinforces Viablife's commitment to advancing sustainable, science-driven ingredient solutions for global markets. Viablife's Hydroxytyrosol is for use as an antioxidant in various foods such as butter, margarine, oil, and shortening, salad dressing, mayonnaise and mayonnaise-type sandwich spreads as well as ready-to-drink sports drinks, "energy" drinks, milk-based meal replacements, flavored water, and fruit flavored drinks, fruit juices, fruit nectars, and vegetable juices.

"Our mission at Viablife is to revolutionize the way bioactive compounds are produced, making them more sustainable and accessible to the industry," said Justin Han, Director of Health and Nutrition Division at Hangzhou Viablife Biotech Co., Ltd. "Achieving an FDA No Objection status for Hydroxytyrosol is a testament to the strategy, safety, efficacy, and scalability of our technological approach as well as overall capabilities. We are grateful to the team at REJIMUS for their incredible regulatory guidance and unwavering support throughout this process."

"Viablife's success in obtaining GRAS Status from the FDA reflects the company's dedication to high-quality, purpose-driven food ingredient innovation and services, which perfectly aligns with our mission," said Brandon M. Griffin, CEO at REJIMUS, INC. "We are extremely proud to have supported this effort from start to finish and look forward to seeing this ingredient and the Viablife team flourish."

With this regulatory clearance, Viablife is positioned to greatly expand its market presence in the U.S., offering product manufacturers and leading CPG brands a reliable, sustainable source of high-purity Hydroxytyrosol for a wide range of traditional foods and beverages.

Hangzhou Viablife Biotech Co., Ltd.:

Viablife is a hightech enterprise that is specialized in enzymatic synthesis and biomanufacturing of active pharmaceutical ingredients, fine chemicals, natural dyes, advanced intermediates, and food ingredients. To learn more about Viablife's current innovations, ingredients and other resources to U.S. customers, please visit: or

About REJIMUS, Inc.:

REJIMUS, INC. is a preeminent FDA regulatory management consultancy enabling companies in the Food, Dietary Supplement, Cosmetic and Homeopathic/OTC industries to achieve faster time-to-market for novel ingredients and finished consumer product goods with less legal and regulatory risks, while optimizing their quality operations and overall supply-chain. For more information on the markets served and service offerings, please visit:

Media Contact

Dianne Strickland, REJIMUS, INC., 1 682-267-1204, [email protected],  

SOURCE REJIMUS, INC.

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact 51ÔÚÏß

Products

My Services
  • All News Releases
51ÔÚÏß Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025  US Inc.